Our study, in which we performed #aGAPSS validation in our #antiphospholipid syndrome cohort, was published. #APS #thrombosis rdcu.be/b5bK7

lnkd.in/e2g5ikj Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications lnkd.in/e_6HteF

New: A University of Michigan-led study of serum from 172 patients hospitalized with #COVID19 finds blood-clot-promoting autoantibodies in at least half of the samples, helping to explain why some patients experience increased clotting. fcld.ly/f4sgz8v

bugünlerde çağdaş yaşamı destekleme derneği'nin "anadolu'da bir kızım var" kampanyası var. "EGITIM" yazıp 4622'ye göndererek 10 TL bağışlanıyor. sizi bağış yapmaya davet ediyorum. ayrıca bu metni kopyalayıp kendi sayfanızda da paylaşır mısınız?

1/ Glad to see our study on serum and urine biomarkers of disease activity in patients with systemic #lupus erythematosus as an abstract in #ACR21. acrabstracts.org/abstract/serum…

Excited to present our study in #ERA22 as a free communication. Grateful to all contributors starting with Prof. Bahar Artim-Esen. Omer Uludag erdem_gurel_ Sibel Varelci Halil Yazıcı Yasemin Ozluk ERA - European Renal Association YNP of ERA TürkNefrolojiDerneği

It’s been some time since we wrote this, but nice to see it published! Our experience with two different dosing regimens of RTX in relapsed or refractory MN! Ali Rıza Uçar Omer Uludag Yasemin Ozluk ahmet burak dirim Erol Demir Özgür Akın Oto Yasar Caliskan Halil Yazıcı Turkish Journal of Nephrology

2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria In Arthritis & Rheumatology loom.ly/3GI96GQ jointly supported by @acr_rheum and EULAR

Low and standard doses of rituximab showed similar efficacy in patients with relapsed or refractory primary membranous nephropathy, albeit lower doses were associated with more relapses.

Türkiye Klinikleri Romatoloji için Prof. Dr. Bahar Artım Esen editörlüğünde #Lupus Nefriti özel sayısı hazırladık. 🚀 turkiyeklinikleri.com/journal/romato… Ali Rıza Uçar Halil Yazıcı İlay Berke Yasar Caliskan Omer Uludag ayse serra artan Yasemin Ozluk Özgür Akın Oto ahmet burak dirim Mert Öztaş

Our review on AA amyloidosis is online! Thanks to my amazing co-authors (Omer Uludag Ozge Hurdogan gizem kumru İlay Berke Eleni Frangou), and Andreas Kronbichler for the invitation! TürkNefrolojiDerneği YNP of ERA link.springer.com/article/10.100…

We have completed this quite a while ago, but nice to see it finally published. These molecules did not outperform conventional biomarkers like serum C3 and C4 in SLE. #lupus TürkNefrolojiDerneği Omer Uludag erdem_gurel_ Sibel Varelci Yasemin Ozluk Halil Yazıcı journals.tubitak.gov.tr/medical/vol54/…

We are pleased to announce that our paper regarding the largest single-center cohort of Budd-Chiari syndrome patients with APS is now available online. #APS #ThrombosisResearch journals.sagepub.com/doi/10.1177/09…

🚨🚨🚨 AHHH we have just been granted a 🔓 FREE 50-DAY ACCESS LINK to the expert #consensus on the therapeutic management of RARE systemic #lupus erythematosus manifestations Can you please re-tweet the link so that a MAXIMUM have access for free 🔄 LINK: authors.elsevier.com/a/1l8og9UBHvvg…

Just published Science Magazine Engineering T cells within the body, a big step forward for treating cancer and autoimmune diseases, as demonstrated in animal models science.org/doi/10.1126/sc… science.org/doi/10.1126/sc…

Thrilled to contribute—the revised, weighted SDI will better reflect the many dimensions of lupus damage. #Lupus #SLE #MCDM

In a trial involving participants with systemic lupus erythematosus, the incidence of a clinical response was higher with telitacicept than with placebo, although infections and reduced immunoglobulin levels were more common. Full 18C010 phase 3 trial results:

✅ Great news! 🙌 New EULAR 2025 recommendations for the management of SLE with kidney Involvement have just been published in Annals of the Rheumatic Diseases. Congrats to all authors for this 🔝 work! Hans-Joachim Anders Jeanette Andersen Marios Kouloumas Ioannis Parodis et al.! ard.eular.org/article/S0003-…

New content online: Cutaneous lupus erythematosus — from pathogenesis to targeted therapy bit.ly/47sQ3nN

Presented at the 15th European Lupus Meeting: In patients with SLE without advanced lupus nephritis, obinutuzumab plus standard therapy was superior to placebo plus standard therapy in conferring and sustaining a clinically meaningful reduction in disease activity over 52